<article id="almenar_2009" class="slide" data-ag-slide-name="Almenar 2009">
    <div class="basic">
      <h1 data-ag-editable="Almenar 2009 Main Title">Neulasta<sup>®</sup> just once per cycle* provides a tailored way to reduce your patient’s risk of neutropenia and its complications<sup>1</sup></h1>
      <!--<div id="ne_page3_data_top"><p></p></div>-->
      <div id="ne_page3_section1">
          <p id="almenar_2009_graph1_legend1" data-ag-editable="Almenar 2009 Graph 1 Legend 1">Neulasta<sup>®</sup></p>
          <p id="almenar_2009_graph1_legend2" data-ag-editable="Almenar 2009 Graph 1 Legend 2">Daily G-CSF</p>
          <p id="almenar_2009_graph2_legend1" data-ag-editable="Almenar 2009 Graph 2 Legend 1">Neulasta<sup>®</sup></p>
          <p id="almenar_2009_graph2_legend2" data-ag-editable="Almenar 2009 Graph 2 Legend 2">Daily G-CSF</p>
          <p id="almenar_2009_graph3_legend1" data-ag-editable="Almenar 2009 Graph 3 Legend 1">Neulasta<sup>®</sup></p>
          <p id="almenar_2009_graph3_legend2" data-ag-editable="Almenar 2009 Graph 3 Legend 2">Daily G-CSF</p>
         <div id="ne_page3_section1_image"></div>
         <div id="ne_page3_section1_data_holder" class="main_content_style ne_page3_section_data">
            <h2 data-ag-editable="Almenar 2009 Content 1 Title">Less than half</h2>
            <p data-ag-editable="Almenar 2009 Content 1 Copy">the incidence of febrile neutropenia<sup>1</sup></p>
            <div class="ne_page3_section_graph_holder">
               <div id="ne_page3_section1_arrow"></div>
               <div id="ne_page3_section1_bar1"><p data-ag-editable="Almenar 2009 Content 1 left %">10.7%</p></div>
               <div id="ne_page3_section1_vs_icon" class="ne_page3_section_vs_icon">
                  <img src="content/images/carer_pages/neulasta_efficacy/ne_page2_section_vs_icon.png" width="25" height="25" data-ag-editable="Almenar 2009 Content 1 VS Icon" />
               </div>
               <div id="ne_page3_section1_bar2"><p data-ag-editable="Almenar 2009 Content 1 right %">24.3%</p></div>
               <div class="ne_page3_section_key"></div>
               <div class="ne_page3_section_main_key">
                  <img src="content/images/carer_pages/neulasta_efficacy/ne_page2_section_main_key.png" width="94" height="30" data-ag-editable="Almenar 2009 Content 1 Key" />
               </div>
            </div>
         </div>
      </div>
      <div id="ne_page3_section2">
         <div id="ne_page3_section2_image"></div>
         <div id="ne_page3_section2_data_holder" class="main_content_style ne_page3_section_data">
            <h2 data-ag-editable="Almenar 2009 Content 2 Title">Two-thirds fewer</h2>
            <p data-ag-editable="Almenar 2009 Content 2 Copy">neutropenia related dose reductions<sup>1</sup></p>
            <div class="ne_page3_section_graph_holder">
               <div id="ne_page3_section2_arrow"></div>
               <div id="ne_page3_section2_bar1"><p data-ag-editable="Almenar 2009 Content 2 left %">6.7%</p></div>
               <div id="ne_page3_section2_vs_icon" class="ne_page3_section_vs_icon">
                  <img src="content/images/carer_pages/neulasta_efficacy/ne_page2_section_vs_icon.png" width="25" height="25" data-ag-editable="Almenar 2009 Content 2 VS Icon" />
               </div>
               <div id="ne_page3_section2_bar2"><p data-ag-editable="Almenar 2009 Content 2 right %">20.7%</p></div>
               <div class="ne_page3_section_key"></div>
               <div class="ne_page3_section_main_key">
                  <img src="content/images/carer_pages/neulasta_efficacy/ne_page2_section_main_key.png" width="94" height="30" data-ag-editable="Almenar 2009 Content 2 Key" />
               </div>
            </div>
         </div>
      </div>
      <div id="ne_page3_section3">
         <div id="ne_page3_section3_image"></div>
         <div id="ne_page3_section3_data_holder" class="main_content_style ne_page3_section_data">
            <h2 data-ag-editable="Almenar 2009 Content 3 Title">Less than half</h2>
            <p data-ag-editable="Almenar 2009 Content 3 Copy">for hospitalization due to FN<sup>1</sup></p>
            <div class="ne_page3_section_graph_holder">
               <div id="ne_page3_section3_arrow"></div>
               <div id="ne_page3_section3_bar1"><p data-ag-editable="Almenar 2009 Content 3 left %">9.3%</p></div>
               <div id="ne_page3_section3_vs_icon" class="ne_page3_section_vs_icon">
                  <img src="content/images/carer_pages/neulasta_efficacy/ne_page2_section_vs_icon.png" width="25" height="25" data-ag-editable="Almenar 2009 Content 3 VS Icon" />
               </div>
               <div id="ne_page3_section3_bar2"><p data-ag-editable="Almenar 2009 Content 3 right %">19.8%</p></div>
               <div class="ne_page3_section_key"></div>
               <div class="ne_page3_section_main_key">
                  <img src="content/images/carer_pages/neulasta_efficacy/ne_page2_section_main_key.png" width="94" height="30" data-ag-editable="Almenar 2009 Content 3 Key" />
               </div>
            </div>
         </div>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="almenar_2009_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Almenar 2009 References Title">References:</strong></p>
          <div data-ag-editable="Almenar 2009 References List">
             <ol>
                <li>Almenar D<em> et al</em>. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study. Eur J Cancer Care (Engl). 2009; 18(3):280-286</li>
             </ol>
          </div>
          <p data-ag-editable="Almenar 2009 References Bottom Copy">* 24 hours after chemotherapy, Neulasta<sup>®</sup> SmPC October 2011</p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>